ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A-to-I editing manner

Abstract

Aberrant A-to-I RNA editing, mediated by ADAR1 has been found to be associated with increased tumourigenesis and the development of chemotherapy resistance in various types of cancer. Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with a poor prognosis, and overcoming chemotherapy resistance poses a significant clinical challenge. This study aimed to clarify the roles of ADAR1 in tumour resistance to cisplatin in iCCA. We discovered that ADAR1 expression is elevated in iCCA patients, particularly in those resistant to cisplatin, and associated with poor clinical outcomes. Downregulation of ADAR1 can increase the sensitivity of iCCA cells to cisplatin treatment, whereas its overexpression has the inverse effect. By integrating RNA sequencing and Sanger sequencing, we identified BRCA2, a critical DNA damage repair gene, as a downstream target of ADAR1 in iCCA. ADAR1 mediates the A-to-I editing in BRCA2 3’UTR, inhibiting miR-3157-5p binding, consequently increasing BRCA2 mRNA and protein levels. Furthermore, ADAR1 enhances cellular DNA damage repair ability and facilitates cisplatin resistance in iCCA cells. Combining ADAR1 targeting with cisplatin treatment markedly enhances the anticancer efficacy of cisplatin. In conclusion, ADAR1 promotes tumour progression and cisplatin resistance of iCCA. ADAR1 targeting could inform the development of innovative combination therapies for iCCA.

References

[1] SiricaAE, Strazzabosco M, CadamuroM. Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 2021;149:321-387.

[2] MorisD, PaltaM, KimC, AllenPJ, MorseMA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198-222.

[3] ZhouY, GuQ, ZhuL, et al. High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma. Cell Prolif. 2023;56:e13513.

[4] XingH, TanB, YangC, Zhang M. Incidence trend and competing risk analysis of patients with intrahepatic cholangiocarcinoma: a population-based study. Front Med (Lausanne). 2022;9:846276.

[5] CilloU, Fondevila C, DonadonM, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143-155.

[6] GoeppertB, TothR, SingerS, et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology. 2019;69:2091-2106.

[7] OlaizolaP, Perugorria MJ, BanalesJM. Toward personalized medicine for intrahepatic cholangiocarcinoma: pharmacogenomic stratification of patients. Hepatology. 2018;68:811-814.

[8] YoungSE, Sritharan R, SiaD. Genomic alterations in intrahepatic cholangiocarcinoma. Hepatoma Res. 2023;9:34.

[9] GolanT, Raitses-Gurevich M, KelleyRK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017;22:804-810.

[10] JiangQ, CrewsLA, HolmF, Jamieson CHM. RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer. 2017;17:381-392.

[11] SlotkinW, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5:105.

[12] WangHM, ChenSN, WeiJY, Song GQ, ZhaoYC. A-to-I RNA editing in cancer: from evaluating the editing level to exploring the editing effects. Front Oncol. 2021;10:10.

[13] GumireddyK, LiA, KossenkovAV, et al. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis. Nat Commun. 2016;7:10715.

[14] ChenL, LiY, LinCH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013;19:209-216.

[15] HanSW, KimHP, ShinJY, et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J Exp Med. 2014;211:613-621.

[16] HuangCS, ZhuYQ, XuQC, et al. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clin Transl Med. 2022;12:e848.

[17] HuangCS, ChuJ, ZhuXX, et al. The C/EBPβ-LINC01133 Axis Promotes Cell Proliferation in Pancreatic Ductal Adenocarcinoma Through Upregulation of CCNG1. Cancer Lett. 2018;421:63-72.

[18] PicardiE, PesoleG. REDItools: high-throughput RNA editing detection made easy. Bioinformatics. 2013;29:1813-1814.

[19] VogelOA, HanJ, LiangCY, Manicassamy S, PerezJT, ManicassamyB. The p150 isoform of ADAR1 blocks sustained RLR signaling and apoptosis during influenza virus infection. PLoS Pathog. 2020;16:e1008842.

[20] SunT, YuY, WuX, et al. Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms. Proc Natl Acad Sci U S A. 2021;118:e2021757118.

[21] YoshidaK, MikiY. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866-871.

[22] XieC, LuoJ, HeY, JiangL, ZhongL, Shi Y. BRCA2 gene mutation in cancer. Medicine (Baltim). 2022;101:e31705.

[23] TungNM, GarberJE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119:141-152.

[24] TomaoF, BardhiE, Di PintoA, et al. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev. 2019;80:101909.

[25] TungN, ArunB, HackerMR, et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). J Clin Oncol. 2020;38:1539-1548.

[26] MayrCA-O. What are 3’TRs doing? Cold Spring Harb Perspect Biol. 2019;11(10):a034728.

[27] YousafA, KimJU, EliahooJ, Taylor-Robinson SD, KhanSA. Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Clin Exp Hepatol. 2019;9:740-748.

[28] WangN, MaT, YuB. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8:69.

[29] LiF, ChenS, YuJ, et al. Interplay of m(6) A and histone modifications contributes to temozolomide resistance in glioblastoma. Clin Transl Med. 2021;11:e553.

[30] XuQC, TienYC, ShiYH, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner. Oncogene. 2022;41:1622-1633.

[31] DaviesAA, MassonJY, McIlwraithMJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell. 2001;7:273-282.

[32] CarotenutoM, SaccoA, ForgioneL, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Explor Target Antitumor Ther. 2022;3:200-223.

[33] MendozaHG, MatosVJ, ParkS, Pham KM, BealPA. Selective inhibition of ADAR1 using 8-azanebularine-modified RNA duplexes. Biochemistry. 2023;62:1376-1387.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.